Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 05 02:01PM ET
0.2550
Dollar change
-0.0151
Percentage change
-5.59
%
Index- P/E- EPS (ttm)-0.27 Insider Own0.56% Shs Outstand85.11M Perf Week-11.15%
Market Cap21.70M Forward P/E- EPS next Y-0.08 Insider Trans0.00% Shs Float84.64M Perf Month-41.93%
Income-19.92M PEG- EPS next Q-0.02 Inst Own3.89% Short Float1.30% Perf Quarter-58.44%
Sales21.99M P/S0.99 EPS this Y91.44% Inst Trans-78.09% Short Ratio1.41 Perf Half Y-63.39%
Book/sh0.11 P/B2.40 EPS next Y-8.69% ROA-37.72% Short Interest1.10M Perf Year-83.86%
Cash/sh0.34 P/C0.74 EPS next 5Y- ROE-184.09% 52W Range0.25 - 1.89 Perf YTD-83.76%
Dividend Est.- P/FCF- EPS past 5Y21.53% ROI-71.70% 52W High-86.51% Beta1.41
Dividend TTM- Quick Ratio1.37 Sales past 5Y0.00% Gross Margin65.79% 52W Low2.00% ATR (14)0.04
Dividend Ex-Date- Current Ratio1.52 EPS Y/Y TTM68.50% Oper. Margin-126.62% RSI (14)29.66 Volatility9.18% 10.79%
Employees38 Debt/Eq3.48 Sales Y/Y TTM- Profit Margin-90.57% Recom1.00 Target Price4.57
Option/ShortYes / Yes LT Debt/Eq2.26 EPS Q/Q71.90% Payout- Rel Volume1.24 Prev Close0.27
Sales Surprise-6.56% EPS Surprise100.00% Sales Q/Q- EarningsNov 25 BMO Avg Volume777.93K Price0.25
SMA20-32.31% SMA50-41.01% SMA200-62.98% Trades Volume683,231 Change-5.59%
Date Action Analyst Rating Change Price Target Change
May-18-17Upgrade Maxim Group Hold → Buy $1 → $3
Feb-13-17Initiated Rodman & Renshaw Buy $3
Aug-12-16Downgrade Maxim Group Buy → Hold $4 → $1
Aug-17-15Reiterated Maxim Group Buy $8 → $4
Jul-27-15Reiterated ROTH Capital Buy $10.50 → $7
Jun-22-15Initiated JMP Securities Mkt Outperform $5
Nov-26-24 10:00AM
Nov-25-24 07:00AM
Nov-22-24 06:35AM
Nov-21-24 06:30AM
Nov-20-24 07:19AM
09:00AM Loading…
Nov-05-24 09:00AM
Oct-16-24 07:00AM
Sep-17-24 01:01PM
Aug-15-24 07:00AM
Aug-08-24 07:00AM
Jun-18-24 07:37AM
Jun-05-24 03:17PM
May-30-24 07:00AM
May-29-24 08:03AM
May-28-24 11:53AM
07:00AM Loading…
07:00AM
May-24-24 07:00AM
May-22-24 07:00AM
May-17-24 05:00PM
May-06-24 07:00AM
Apr-17-24 07:00AM
Apr-10-24 07:00AM
Apr-01-24 09:00AM
Mar-27-24 12:23PM
Mar-26-24 07:00AM
Mar-20-24 07:00AM
Mar-06-24 08:00AM
Mar-04-24 07:00AM
Feb-28-24 07:00AM
Feb-25-24 02:12PM
07:00AM Loading…
Feb-16-24 07:00AM
Dec-21-23 07:00AM
Nov-21-23 03:45PM
Nov-20-23 07:00AM
Nov-13-23 07:00AM
Nov-02-23 03:12PM
Oct-31-23 09:00AM
Oct-30-23 11:38AM
Oct-12-23 07:00AM
Sep-28-23 07:00AM
Sep-19-23 07:00AM
Sep-14-23 05:36AM
Sep-11-23 07:00AM
Sep-05-23 06:04AM
Aug-31-23 08:18AM
Aug-30-23 07:00AM
Aug-22-23 07:00AM
Aug-07-23 02:34PM
Jul-18-23 03:22PM
Jul-17-23 07:00AM
Jun-29-23 02:00PM
Jun-07-23 05:25AM
May-24-23 07:00AM
May-17-23 07:00AM
May-04-23 01:56PM
Apr-25-23 07:00AM
Apr-17-23 11:00AM
Apr-04-23 08:21PM
Mar-24-23 07:15AM
Mar-23-23 11:42AM
Mar-22-23 07:00AM
Mar-15-23 07:00AM
Mar-06-23 07:00AM
Jan-04-23 07:00AM
Dec-20-22 12:36PM
07:00AM
Dec-05-22 04:00AM
Nov-28-22 04:30PM
Nov-15-22 07:00AM
Nov-10-22 04:30PM
07:00AM
Nov-04-22 04:30PM
Nov-03-22 09:11AM
Nov-02-22 09:21AM
Sep-27-22 07:00AM
Sep-19-22 08:00AM
Sep-15-22 12:38PM
07:00AM
Sep-12-22 07:00AM
Aug-18-22 07:47AM
Aug-16-22 07:00AM
Aug-11-22 07:00AM
Jun-29-22 08:00AM
Jun-28-22 07:00AM
Jun-16-22 07:00AM
May-12-22 10:16AM
May-11-22 07:00AM
May-05-22 07:00AM
Mar-17-22 08:55AM
Mar-16-22 07:00AM
Mar-10-22 07:00AM
Mar-03-22 07:00AM
Jan-31-22 04:20AM
Jan-24-22 07:00AM
Jan-18-22 07:00AM
Dec-17-21 07:00AM
Dec-15-21 07:00AM
Nov-18-21 07:00AM
Nov-12-21 07:16AM
Nov-04-21 09:15AM
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.